Table 3.
Assessment of covariates in patients adjusted in 1:1 greedy propensity-score matching.
| Propensity-Score Matched Cohort | ||||
|---|---|---|---|---|
| DN vs. NDN | DN (n = 290) | NDN (n = 290) | OR (95% CI) | p |
| Sex | 1.00 (0.72–1.39) | 1.000 | ||
| Male | 158 (54.5) | 158 (54.5) | ||
| Female | 132 (45.5) | 132 (45.5) | ||
| Age | 69.1 ± 11.8 | 69.1 ± 12.0 | 0.992 | |
| Comorbidity | ||||
| HTN | 195 (67.2) | 195 (67.2) | 1.00 (0.71–1.42) | 1.000 |
| CAD | 27 (9.3) | 27 (9.3) | 1.00 (0.57–1.75) | 1.000 |
| CHF | 1 (0.3) | 1 (0.3) | 1.00 (0.06–16.06) | 1.000 |
| CVA | 33 (11.4) | 33 (11.4) | 1.00 (0.60–1.67) | 1.000 |
| ESRD | 0 | 0 | - | - |
| ISS, median (IQR) | 16 (9–20) | 16 (9–20) | - | 0.696 |
| SIH vs. NDN | SIH (n = 214) | NDN (n = 214) | OR (95% CI) | p |
| Sex | 1.00 (0.67–1.49) | 1.000 | ||
| Male | 138 (64.5) | 138 (64.5) | ||
| Female | 76 (35.5) | 76 (35.5) | ||
| Age | 53.8 ± 17.6 | 53.5 ± 17.7 | - | 0.883 |
| Comorbidity | ||||
| HTN | 48 (22.4) | 48 (22.4) | 1.00 (0.64–1.58) | 1.000 |
| CAD | 6 (2.8) | 6 (2.8) | 1.00 (0.32–3.15) | 1.000 |
| CHF | 0 (0.0) | 0 (0.0) | - | - |
| CVA | 3 (1.4) | 3 (1.4) | 1.00 (0.20–5.01) | 1.000 |
| ESRD | 0 (0.0) | 0 (0.0) | - | - |
| ISS, median (IQR) | 24 (16–29) | 24 (16–29) | - | 0.964 |
| DH vs. NDN | DH (n = 200) | NDN (n = 200) | OR (95% CI) | p |
| Sex | 1.00 (0.67–1.49) | 1.000 | ||
| Male | 115 (57.5) | 115 (57.5) | ||
| Female | 85 (42.5) | 85 (42.5) | ||
| Age | 65.4 ± 13.0 | 65.8 ± 13.3 | - | 0.767 |
| Comorbidity | ||||
| HTN | 124 (62.0) | 124 (62.0) | 1.00 (0.67–1.50) | 1.000 |
| CAD | 27 (13.5) | 27 (13.5) | 1.00 (0.56–1.78) | 1.000 |
| CHF | 1 (0.5) | 1 (0.5) | 1.00 (0.06–16.10) | 1.000 |
| CVA | 20 (10.0) | 20 (10.0) | 1.00 (0.52–1.92) | 1.000 |
| ESRD | 0 (0.0) | 0 (0.0) | - | - |
| ISS, median (IQR) | 17 (14–25) | 17 (13.25–25) | - | 0.767 |
| SIH vs. DH | SIH (n = 106) | DH (n = 106) | OR (95% CI) | p |
| Sex | 1.00 (0.58–1.72) | 1.000 | ||
| Male | 61 (57.5) | 61 (57.5) | ||
| Female | 45 (42.5) | 45 (42.5) | ||
| Age | 61.8 ± 15.0 | 61.5 ± 13.9 | - | 0.872 |
| Comorbidity | ||||
| HTN | 42 (39.6) | 42 (39.6) | 1.00 (0.58–1.73) | 1.000 |
| CAD | 5 (4.7) | 5 (4.7) | 1.00 (0.28–3.56) | 1.000 |
| CHF | 0 (0.0) | 0 (0.0) | - | - |
| CVA | 3 (2.8) | 3 (2.8) | 1.00 (0.20–5.07) | 1.000 |
| ESRD | 0 (0.0) | 0 (0.0) | - | - |
| ISS, median (IQR) | 20 (16–25) | 20 (16–25) | - | 0.998 |
HTN = hypertension; CAD = coronary artery disease; CHF = congestive heart failure; CVA = cerebral vascular accident; ESRD = end-stage renal disease; ISS = injury severity score; IQR = interquartile range; ICU = intensive care unit; LOS = length of stay; NDN = nondiabetic normoglycemia; DN = diabetic normoglycemia; SIH = stress-induced hyperglycemia; DH = diabetic hyperglycemia.